{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:18:32Z","timestamp":1792919912518,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00277-024-06121-z","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T04:22:10Z","timestamp":1736482930000},"page":"1139-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Laiba","family":"Shakeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Khaliq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsheen","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumaisa","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Um E Abiha","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Twaha","family":"Zia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymar","family":"Akilimali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"6121_CR1","unstructured":"Puckett YC (2023). Acute lymphocytic leukemia [Internet] [cited 2023 Dec 6]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459149\/"},{"key":"6121_CR2","doi-asserted-by":"crossref","unstructured":"Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M (2018) T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev [Internet]. Jan 1 [cited 2023 Dec 6];32(1):36\u201351. https:\/\/pubmed.ncbi.nlm.nih.gov\/28830639\/","DOI":"10.1016\/j.blre.2017.08.006"},{"key":"6121_CR3","doi-asserted-by":"crossref","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007. Blood [Internet]. Jan 5 [cited 2023 Dec 6];119(1):34\u201343. https:\/\/pubmed.ncbi.nlm.nih.gov\/22086414\/","DOI":"10.1182\/blood-2011-04-347872"},{"key":"6121_CR4","doi-asserted-by":"crossref","unstructured":"Caracciolo D, Mancuso A, Poler\u00e0 N, Froio C, D\u2019Aquino G, Riillo C et al. (2023) The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Exp Hematol Oncol [Internet]. Dec 1 [cited 2023 Dec 6];12(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/36624522\/","DOI":"10.1186\/s40164-022-00368-w"},{"issue":"4","key":"6121_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.htct.2019.09.005","volume":"42","author":"JC Jaime-P\u00e9rez","year":"2020","unstructured":"Jaime-P\u00e9rez JC, Santos JAH, de los, G\u00f3mez-Almaguer D (2020) Childhood T-cell acute lymphoblastic leukemia in a single latin American center: impact of improved treatment scheme and support therapy on survival. Hematol Transfus Cell Ther 42(4):320\u2013325","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"6121_CR6","doi-asserted-by":"publisher","first-page":"a035246","DOI":"10.1101\/cshperspect.a035246","volume":"10","author":"F Gianni","year":"2020","unstructured":"Gianni F, Belver L, Ferrando A (2020) The Genetics and mechanisms of T-Cell Acute Lymphoblastic Leukemia. Cold Spring Harb Perspect Med 10(3):a035246","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"6121_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/10428194.2018.1522442","volume":"60","author":"GS Guru Murthy","year":"2019","unstructured":"Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E (2019) Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. Leuk Lymphoma 60(5):1171\u20131178","journal-title":"Leuk Lymphoma"},{"key":"6121_CR8","doi-asserted-by":"crossref","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ (2020) Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol [Internet]. Jun 5 [cited 2023 Dec 6];13(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/32503572\/","DOI":"10.1186\/s13045-020-00905-2"},{"key":"6121_CR9","doi-asserted-by":"crossref","unstructured":"Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S et al. (2021) Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer [Internet]. Jul 1 [cited 2023 Dec 6];151:175\u201389. https:\/\/pubmed.ncbi.nlm.nih.gov\/34010787\/","DOI":"10.1016\/j.ejca.2021.03.034"},{"key":"6121_CR10","doi-asserted-by":"crossref","unstructured":"Styczy\u0144ski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S et al (2020) Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant [Internet]. Jan 1 [cited 2023 Dec 6];55(1):126\u201336. https:\/\/pubmed.ncbi.nlm.nih.gov\/31455899\/","DOI":"10.1038\/s41409-019-0624-z"},{"key":"6121_CR11","doi-asserted-by":"crossref","unstructured":"Cohen MH, Johnson JR, Justice R, Pazdur R (2008) FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Oncologist [Internet]. Jun 1 [cited 2023 Dec 6];13(6):709\u201314. https:\/\/pubmed.ncbi.nlm.nih.gov\/18586926\/","DOI":"10.1634\/theoncologist.2006-0017"},{"key":"6121_CR12","doi-asserted-by":"crossref","unstructured":"Buie LW, Epstein SS, Lindley CM (2007) Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther [Internet]. Sep [cited 2023 Dec 6];29(9):1887\u201399. https:\/\/pubmed.ncbi.nlm.nih.gov\/18035189\/","DOI":"10.1016\/j.clinthera.2007.09.002"},{"key":"6121_CR13","doi-asserted-by":"crossref","unstructured":"Roecker AM, Stockert A, Kisor DF (2010) Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol [Internet]. [cited 2023 Dec 6];4:133\u201341. https:\/\/pubmed.ncbi.nlm.nih.gov\/21151585\/","DOI":"10.4137\/CMO.S4364"},{"key":"6121_CR14","doi-asserted-by":"crossref","unstructured":"Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M et al (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group. J Clin Oncol [Internet]. [cited 2024 Aug 19];23(15):3376\u201382. https:\/\/pubmed.ncbi.nlm.nih.gov\/15908649\/","DOI":"10.1200\/JCO.2005.03.426"},{"key":"6121_CR15","doi-asserted-by":"crossref","unstructured":"Abaza Y, Kantarjian M, Faderl H, Jabbour S, Jain E, Thomas ND (2018) Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol [Internet]. 2018 Jan 1 [cited 2024 Aug 19];93(1):91\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/29047158\/","DOI":"10.1002\/ajh.24947"},{"key":"6121_CR16","doi-asserted-by":"crossref","unstructured":"Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C et al. (2020) Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am J Hematol [Internet]. Dec 1 [cited 2024 Aug 19];95(12):1466\u201372. https:\/\/pubmed.ncbi.nlm.nih.gov\/32777149\/","DOI":"10.1002\/ajh.25957"},{"key":"6121_CR17","doi-asserted-by":"crossref","unstructured":"Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T et al. (2023) Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. Lancet Haematol [Internet]. Jun 1 [cited 2024 Aug 19];10(6):e419\u201332. https:\/\/pubmed.ncbi.nlm.nih.gov\/37167992\/","DOI":"10.1016\/S2352-3026(23)00072-8"},{"key":"6121_CR18","doi-asserted-by":"crossref","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z et al. (2020) Children\u2019s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol [Internet]. Oct 1 [cited 2024 Aug 19];38(28):3282\u201393. https:\/\/pubmed.ncbi.nlm.nih.gov\/32813610\/","DOI":"10.1200\/JCO.20.00256"},{"key":"6121_CR19","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. Mar 29 [cited 2024 Apr 20];372. https:\/\/www.bmj.com\/content\/372\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"6121_CR20","unstructured":"Study Quality Assessment Tools| NHLBI NIH [Internet]. [cited 2024 Apr 20]. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"6121_CR21","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. Aug 28 [cited 2024 Aug 19];366. https:\/\/www.bmj.com\/content\/366\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"6121_CR22","doi-asserted-by":"publisher","unstructured":"Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM et al. (2023) Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia. Blood Adv [Internet]. Apr 11 [cited 2024 Aug 19];7(7):1092\u2013102. https:\/\/doi.org\/10.1182\/bloodadvances.2022008280","DOI":"10.1182\/bloodadvances.2022008280"},{"key":"6121_CR23","doi-asserted-by":"crossref","unstructured":"Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M et al. (2017) Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol [Internet]. Oct 1 [cited 2024 Aug 19];179(2):284\u201393. https:\/\/pubmed.ncbi.nlm.nih.gov\/28771663\/","DOI":"10.1111\/bjh.14874"},{"key":"6121_CR24","doi-asserted-by":"crossref","unstructured":"Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD, Abraham S et al (2006) Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia\/lymphoma. Clin Cancer Res [Internet]. Sep 15 [cited 2024 Aug 19];12(18):5329\u201335. https:\/\/pubmed.ncbi.nlm.nih.gov\/17000665\/","DOI":"10.1158\/1078-0432.CCR-06-0606"},{"key":"6121_CR25","doi-asserted-by":"crossref","unstructured":"Commander LA, Seif AE, Insogna IG, Rheingold SR (2010) Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol [Internet]. Aug [cited 2024 Aug 19];150(3):345\u201351. https:\/\/pubmed.ncbi.nlm.nih.gov\/20528871\/","DOI":"10.1111\/j.1365-2141.2010.08236.x"},{"issue":"1","key":"6121_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/10428190600961058","volume":"48","author":"M Czuczman","year":"2007","unstructured":"Czuczman M, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi E et al (2007) Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma 48(1):97\u2013103","journal-title":"Leuk Lymphoma"},{"key":"6121_CR27","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Basara N, Baurmann H, Beck J, Br\u00fcggemann M, Diedrich H et al (2011) High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation. Blood [Internet]. Sep 29 [cited 2024 Aug 19];118(13):3504\u201311. https:\/\/pubmed.ncbi.nlm.nih.gov\/21715318\/","DOI":"10.1182\/blood-2011-01-329441"},{"key":"6121_CR28","doi-asserted-by":"crossref","unstructured":"Kuhlen M, Bleckmann K, M\u00f6ricke A, Schrappe M, Vieth S, Escherich G et al (2017) Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. Br J Haematol [Internet]. Oct 1 [cited 2024 Aug 19];179(2):272\u201383. https:\/\/pubmed.ncbi.nlm.nih.gov\/28771662\/","DOI":"10.1111\/bjh.14877"},{"key":"6121_CR29","doi-asserted-by":"crossref","unstructured":"Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP et al (2012) Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol [Internet]. Aug 1 [cited 2024 Aug 19];30(22):2753\u20139. https:\/\/pubmed.ncbi.nlm.nih.gov\/22734022\/","DOI":"10.1200\/JCO.2011.40.8724"},{"key":"6121_CR30","doi-asserted-by":"crossref","unstructured":"Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL et al (2015) Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0434. Pediatr Blood Cancer [Internet]. Jul 1 [cited 2024 Aug 19];62(7):1176\u201383. https:\/\/pubmed.ncbi.nlm.nih.gov\/25755211\/","DOI":"10.1002\/pbc.25470"},{"key":"6121_CR31","doi-asserted-by":"publisher","unstructured":"DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT et al (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood [Internet]. Jun 15 [cited 2024 Aug 19];109(12):5136\u201342. https:\/\/doi.org\/10.1182\/blood-2006-11-056754","DOI":"10.1182\/blood-2006-11-056754"},{"key":"6121_CR32","doi-asserted-by":"crossref","unstructured":"Yanagi M, Mori M, Honda M, Mitani Y, Seki M, Fukuoka K et al (2024) Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma. Int J Hematol [Internet]. Mar 1 [cited 2024 Aug 19];119(3):327\u201333. https:\/\/pubmed.ncbi.nlm.nih.gov\/38302839\/","DOI":"10.1007\/s12185-023-03701-z"},{"issue":"9617","key":"6121_CR33","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. Lancet 371(9617):1030\u20131043","journal-title":"Lancet"},{"key":"6121_CR34","doi-asserted-by":"crossref","unstructured":"Reilly KM, Kisor DF (2009) Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther [Internet]. Aug [cited 2024 Aug 19];2:219. \/pmc\/articles\/PMC2886323\/","DOI":"10.2147\/OTT.S4770"},{"key":"6121_CR35","doi-asserted-by":"publisher","unstructured":"Kathpalia M, Mishra P, Bajpai R, Bhurani D, Agarwal N (2022) Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Ann Hematol [Internet]. Aug 1 [cited 2024 Aug 19];101(8):1655\u201366. https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00277-022-04880-1","DOI":"10.1007\/s00277-022-04880-1"},{"key":"6121_CR36","doi-asserted-by":"crossref","unstructured":"Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF et al (2005) Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol [Internet]. [cited 2024 Aug 12];23(15):3396\u2013403. https:\/\/pubmed.ncbi.nlm.nih.gov\/15908652\/","DOI":"10.1200\/JCO.2005.03.199"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06121-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06121-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06121-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:40:49Z","timestamp":1743889249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06121-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6121"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06121-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors read and approved the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support and sponsorship"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Presentation"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}